NEW YORK – Anatomic pathology firm Sakura Finetek and imaging company Hamamatsu Photonics announced on Friday an alliance to standardize digital pathology slides and images. The companies intend to ...
NEW YORK – Trinity Biotech announced on Thursday that it has entered into a collaboration agreement with the University at Buffalo in New York to commercialize proprietary novel biomarkers for Sjögren ...
The research team created a point-of-care assay that can detect bacterial STIs, including chlamydia and gonorrhea.
In February, the US Food and Drug Administration granted 510(k) clearance to a dozen in vitro diagnostic tests encompassing molecular, immunoassay, clinical chemistry, and ion selective electrode ...
The companies will explore co-commercializing Labcorp's PGDx Elio Plasma Focus Dx liquid biopsy assay alongside Illumina's TruSight Oncology Comprehensive solid tumor test.
Last week, readers were most interested in a story about AltraTech moving its HIV viral load test moving toward commercialization with the help of a Gates Foundation grant.
In a statement, the firm's President and CEO Zhenya Lindgardt noted that in 2025 Sera pivoted from clinical validation to commercial operation.
The test allows for quantitative measurement of the protein neurofilament light chain – a marker of neuroaxonal injury – in plasma and serum.
The Michigan startup uses a proprietary approach called processor-mediated PCR to enable high-plex, low-cost testing in a single tube.
The company's BV Flex test measures patient immune proteins in capillary blood samples to determine whether an individual has a bacterial or viral infection.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results